{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:20:35Z","timestamp":1790144435648,"version":"4.0.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T00:00:00Z","timestamp":1719619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["005278123"],"award-info":[{"award-number":["005278123"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["NELSON20QI0"],"award-info":[{"award-number":["NELSON20QI0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jcf.2024.06.010","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T11:53:57Z","timestamp":1721994837000},"page":"642-651","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Wellness in the modulator era: An observational study of the impact of CFTR modulator therapy on the well-being of people with cystic fibrosis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2961-5661","authenticated-orcid":false,"given":"Aricca D.","family":"Van Citters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enid","family":"Aliaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A.","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4057-0561","authenticated-orcid":false,"given":"Cynthia D.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Cary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Cravens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla A.","family":"Frederick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0924-4031","authenticated-orcid":false,"given":"Anna M.","family":"Georgiopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher H.","family":"Goss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3916-8260","authenticated-orcid":false,"given":"Traci M.","family":"Kazmerski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel R.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlyn","family":"Lovell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Tillman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2024.06.010_bib0001","unstructured":"Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry: 2022 Annual Data Report Bethesda, MD: Cystic Fibrosis Foundation; 2023."},{"key":"10.1016\/j.jcf.2024.06.010_bib0002","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ccm.2022.06.007","article-title":"The Impact of Highly Effective Modulator Therapy on Cystic Fibrosis Microbiology and Inflammation","volume":"43","author":"Caverly","year":"2022","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.jcf.2024.06.010_bib0003","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ccm.2022.06.009","article-title":"Update on Clinical Outcomes of Highly Effective Modulator Therapy","volume":"43","author":"Gifford","year":"2022","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.jcf.2024.06.010_bib0004","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2024.06.010_bib0005","article-title":"The effect of discontinuing hypertonic saline or dornase alfa on mucociliary clearance in elexacaftor\/tezacaftor\/ivacaftor treated people with cystic fibrosis: the SIMPLIFY-MCC Study","author":"Donaldson","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.06.010_bib0006","doi-asserted-by":"crossref","first-page":"e01015","DOI":"10.1002\/prp2.1015","article-title":"Real-life efficacy and safety of elexacaftor\/tezacaftor\/ivacaftor on severe cystic fibrosis lung disease patients","volume":"10","author":"Kos","year":"2022","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.jcf.2024.06.010_bib0007","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(21)00454-9","article-title":"Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial","volume":"10","author":"Sutharsan","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2024.06.010_bib0008","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/ppul.26260","article-title":"A survey assessing the impact of COVID-19 and elexacaftor\/tezacaftor\/ifavacaftor on both physical and mental health in adults with cystic fibrosis","volume":"58","author":"Sakon","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2024.06.010_bib0009","doi-asserted-by":"crossref","DOI":"10.1177\/17534666221144211","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on depression and anxiety in cystic fibrosis","volume":"16","author":"Zhang","year":"2022","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.jcf.2024.06.010_bib0010","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1002\/ppul.26527","article-title":"Positive and negative impacts of elexacaftor\/tezacaftor\/ivacaftor: healthcare providers' observations across US centers","volume":"58","author":"Bathgate","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2024.06.010_bib0011","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/ppul.26412","article-title":"Management of neuropsychiatric symptoms in adults treated with elexacaftor\/tezacaftor\/ivacaftor","volume":"58","author":"Baroud","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2024.06.010_bib0012","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2022-001420","article-title":"Exploring the impact of elexacaftor-tezacaftor-ivacaftor treatment on opinions regarding airway clearance techniques and nebulisers: TEMPO a qualitative study in children with cystic fibrosis, their families and healthcare professionals","volume":"9","author":"Almulhem","year":"2022","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.jcf.2024.06.010_bib0013","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/jpepsy\/jsq111","article-title":"Acceptance and well-being in adolescents and young adults with cystic fibrosis: a prospective study","volume":"36","author":"Casier","year":"2011","journal-title":"J Pediatr Psychol"},{"key":"10.1016\/j.jcf.2024.06.010_bib0014","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jcf.2009.03.002","article-title":"Health related quality of life in cystic fibrosis: to work or not to work?","volume":"8","author":"Havermans","year":"2009","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.06.010_bib0015","doi-asserted-by":"crossref","DOI":"10.1590\/1984-0462\/2020\/38\/2018397","article-title":"Factors associated to quality of life in children and adolescents with cystic fibrosis","volume":"38","author":"Santana","year":"2020","journal-title":"Rev Paul Pediatr"},{"key":"10.1016\/j.jcf.2024.06.010_bib0016","doi-asserted-by":"crossref","first-page":"147","DOI":"10.17219\/acem\/38147","article-title":"Health-related quality of life of patients suffering from cystic fibrosis","volume":"24","author":"Uchmanowicz","year":"2015","journal-title":"Adv Clin Exp Med"},{"key":"10.1016\/j.jcf.2024.06.010_bib0017","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jcf.2022.08.018","article-title":"Non-respiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor\/tezacaftor\/ivacaftor","volume":"22","author":"Fajac","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.06.010_bib0018","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s11136-009-9496-9","article-title":"Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items","volume":"18","author":"Hays","year":"2009","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jcf.2024.06.010_bib0019","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s11136-013-0581-8","article-title":"Development of the PROMIS (R) pediatric global health (PGH-7) measure","volume":"23","author":"Forrest","year":"2014","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jcf.2024.06.010_bib0020","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1007\/s11136-021-02925-y","article-title":"Minimal important change (MIC): a conceptual clarification and systematic review of MIC estimates of PROMIS measures","volume":"30","author":"Terwee","year":"2021","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jcf.2024.06.010_bib0021","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry (Edgmont)"},{"key":"10.1016\/j.jcf.2024.06.010_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2023.02.009","article-title":"Cystic fibrosis prevalence in the United States and participation in the cystic fibrosis foundation patient registry in 2020","author":"Cromwell","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.06.010_bib0023","first-page":"7","article-title":"An overview of content analysis","author":"Stemier","year":"2001","journal-title":"Prac Assess, Res Eval"},{"key":"10.1016\/j.jcf.2024.06.010_bib0024","article-title":"Global burden of anxiety and depression among cystic fibrosis patient: systematic review and meta-analysis","volume":"2021","author":"Guta","year":"2021","journal-title":"Int J Chronic Dis"},{"key":"10.1016\/j.jcf.2024.06.010_bib0025","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jcf.2023.01.002","article-title":"Cost burden among the CF population in the United States: a focus on debt, food insecurity, housing and health services","volume":"22","author":"Seyoum","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.06.010_bib0026","first-page":"13","article-title":"Advances in the cystic fibrosis drug development pipeline","author":"Esposito","year":"2023","journal-title":"Life (Basel)"},{"key":"10.1016\/j.jcf.2024.06.010_bib0027","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/S0140-6736(23)01608-2","article-title":"The future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches","volume":"402","author":"Graeber","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2024.06.010_bib0028","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S2213-2600(23)00297-7","article-title":"Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2024.06.010_bib0029","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0140-6736(23)01609-4","article-title":"CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis","volume":"402","author":"Taylor-Cousar","year":"2023","journal-title":"Lancet"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324007793?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324007793?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:16:09Z","timestamp":1778822169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324007793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1569199324007793"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.06.010","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Wellness in the modulator era: An observational study of the impact of CFTR modulator therapy on the well-being of people with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}